sacituzumab govitecan
gilead sciences,astrazeneca,daiichi sankyo
['biomarker', 'sacituzumab', 'bcsm']
db-04 will change soc and how we think about her2 as a biomarker. while the hrneg subset was small, clinical outcomes look very compelling. how should we think about this subset, especially in terms of sequencing with sacituzumab? #bcsm #asco22 (1/6) 
Breast Medical Oncologist - @MayoClinic. Focus on #TNBC and #immunoonc. Opinions are mine, not my employer’s. Orgullosamente ecuatoriano ????